Profil
Eric Lohrer has worked as a Director at Amazentis SA since 2015 and is currently employed there.
He also holds a position as Managing Partner at Helvetica Capital AG, where he is currently employed.
Aktive Positionen von Eric Lohrer
| Unternehmen | Position | Beginn |
|---|---|---|
Helvetica Capital AG
 Helvetica Capital AG Investment ManagersFinance Helvetica Capital AG is an independent private equity/venture capital firm headquartered in Zurich, Switzerland. The firm was founded in August 2015 by Johannes Suter. | Private Equity Investor | - |
Amazentis SA
 Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Direktor/Vorstandsmitglied | 01.11.2015 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Helvetica Capital AG
Helvetica Capital AG Investment ManagersFinance Helvetica Capital AG is an independent private equity/venture capital firm headquartered in Zurich, Switzerland. The firm was founded in August 2015 by Johannes Suter. | Finance |
Amazentis SA
Amazentis SA Miscellaneous Commercial ServicesCommercial Services Amazentis SA is a Swiss innovative life science company that focuses on developing products targeting mitochondrial health for advanced nutrition. The company was founded in 2007 by Pierre Landolt, Patrick Aebischer, and Chris Rinsch, and it is currently based in Lausanne, Switzerland. The company has published its research on Mitopure™ Urolithin A in top peer-reviewed scientific journals, including Nature Medicine, Nature Metabolism, JAMA Network Open, and European Journal of Clinical Nutrition. Amazentis has a strategic partnership with Nestlé Health Science to expand the health applications of Mitopure™. Brian Ray has been the CEO of the company since 2023. | Commercial Services |
